Drugs / GQ1001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04450732 | Jul 2020 → Mar 2024 | HER2 positive breast carcinoma, salivary gland carcinoma | GeneQuantum Healthcare (Suzhou) Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05575804 | Oct 2022 → Jan 2025 | HER2 positive breast carcinoma | Fudan University | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-03-15 | GeneQuantum Healthcare (Suzhou) Co., Ltd. | Regulatory Global first iLDC enabling ADC drug receives IND approval by NMPA genequantum.com ↗
GeneQuantum Healthcare (GQ) today announced that the China National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for GQ1001, an in-house developed next generation antibody drug conjugate (ADC) asset. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-03-15 | GeneQuantum Healthcare (Suzhou) Co., Ltd. | Global first iLDC enabling ADC drug receives IND approval by NMPA genequantum.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GQ1001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05575804 ↗ |
| Modality | Other / unclassified | “HER2-targeted antibody-drug conjugate GQ1001” NCT05575804 ↗ |
| Route | Intravenous | “GQ1001 monotherapy was administered intravenously every 3 weeks.” PMID 39789619 ↗ Jan 2025 |